Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Latest Information Update: 13 Jul 2024
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ARCAGY-GINECO; CHIVA; GINECO GINEGEPS
- 04 Jun 2024 Results assessing baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2024 Results analyzing the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 24 Oct 2023 Results assessing links between KELIMTM values and pathological response, and changes in TILs, in ovarian cancer patients treated with neo-adjuvant chemotherapy (NACT) +/- interval debulking surgery, presented at the 48th European Society for Medical Oncology Congress.